Investigation of genotype-specific serum neutralizing activity in children and adolescents immunized with Russian mumps vaccine


Cite item

Full Text

Abstract

Postvaccination immunity was studied in the children and teenagers without a history of clinical mumps infection, who had been immunized with the Leningrad-3 mumps vaccine. The level of specific IgG in ELISA and that and spectrum of their neutralizing activity against a vaccine strain and three heterologous mumps virus (MV) strains (genotypes A, C, and H) were measured. The investigation included 151 sera from the vaccinees aged 3 to 17 years, possessing the detectable specific IgG titers in ELISA and the detectable neutralizing titers against the vaccine strain. 97.4% of the vaccinees had neutralizing activity against 1-3 heterologous MV strains. A preponderance of neutralizing titers against heterologous MV strains by 1-log2 in some sera (6.5-32.5 depending on age) was most likely to suggest that the vaccinees' had been in contact with these virus strains in the past. In our investigation, a combination of positive IgG titers and neutralizing titers against the vaccine strain 2-log2 or higher provided the protection of the vaccinated children and teenagers against the symptomatic infection. There was a pronounced buster effect of the second immunization and a drop in the neutralizing activity of the sera from the vaccinated children and adolescents over time after the first and second immunization.

References

  1. Atrasheuskaya A. V., Neverov A. A., Rubin S. V., Ignatyev G. M. Horizontal transmission of the L-3 live attenuated mumps vaccine virus // Vaccine. - 2006. - Vol. 24. - P. 1530-1536.
  2. Atrasheuskaya A. V., Blatun E. M., Kulak M. V. et al. Investigation of mumps vaccine failures in Minks, Belarus // Vaccine. - 2007. - Vol. 25. - P. 4651-4658.
  3. Atrasheuskaya A. V., Kulak M. V., Rubin S., Ignatyev G. M. Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004 // Clin. Microbiol. Infect. - 2007. - Vol. 13. - P. 670-676.
  4. Date A. A., Kyaw M. H., Rue A. M. et al. Long-term persistence of mumps antibody after receipt of 2 MMR vaccinations and antibody response after a third MMR vaccination among a university population // J. Infect. Dis. - 2008. - Vol. 197. - P. 1662-1668.
  5. Davidkin I., Jokinen S., Broman M. et al. Persistence of measles, mumps and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow up // J. Infect. Dis. - 2008. - Vol. 197. - P. 950-956.
  6. Dayan G. H., Rubin S. Mumps outbreaks in vaccinated populations; are available mumps vaccines effective enough to prevent outbreaks? // Clin. Infect. Dis. - 2008. - Vol. 47. - P. 1458-1467.
  7. Ennis F. A. Immunity to mumps an institutional epidemic: correlation of insusceptibility to mumps with serum plague neutralizing and hemagglutination-inhibiting antibodies // J. Infect. Dis. - 1969. - Vol. 80. - P. 323-329.
  8. Mauldin J., Carbone K., Hsu H. et al. Mumps virus-specific antibody titers from prevaccine era sera: comparison of the plague reduction neutralization assay and enzyme immunoassays // J. Clin. Microbiol. - 2005. - Vol. 43. - P. 844-851.
  9. Narita M., Matsuzono Y., Takekoshi Y. et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G // Clin. Diagn. Lab. Immunol. -1998. - N 5. - P. 79-803.
  10. Nöjd J., Tecle T., Samuelsson A., Örvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype // Vaccine. - 2001. - Vol. 19. - P. 1727-1731.
  11. Norman G. R., Streiner D. L. Biostatistics. The bare essentials. - 2-nd ed. - London, 2000.
  12. Örvell C., Alsheikhly A.-R., Kalantari M., Johansson B. Characterization of genotype-specific epitopes of the HN protein of mumps virus // J. Gen. Virol. - 1997. - Vol. 78. - P. 3187- 3193.
  13. Paunio M., Hedman K., Davidkin I., Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy // Expert Opin. Pharmacother. - 2003. - N 4. - P. 1215-1225.
  14. Pebody R. G., Gay N. J., Hesketh L. M. et al. Immunogenecity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance // Vaccine. - 2002. - Vol. 15. - P. 1134-1140.
  15. Peltola H., Kulkarni P. S., Kapre S. V. et al. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines // Clin. Infect. Dis. - 2007. - Vol. 45. - P. 459-466.
  16. Pipkin P. A., Afzal M. A., Heath A. B. et al. Assay of humoral immunity to mumps virus // J. Virol. Meth. - 1999. - Vol. 79. - P. 219-225.
  17. Rubin S., Mauldin J., Chumakov K. et al. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains // Vaccine. - 2006. - Vol. 24. - P. 2662-2668.
  18. Rubin S. A., Qi L., Audet S. A. et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak // J. Infect. Dis. - 2008. - N 4. - P. 508-515.
  19. WHO-recommended standards for surveillance of selected vaccine-preventable diseases // Vaccines and Biologicals. - 2003. - P. 18-21.
  20. Yoshida N., Fujino M., Miyata A. et al. Mumps virus reinfection is not a rare event confirmed by reverse transcription loop-mediated isothermal amplification // J. Med. Virol. - 2008. - N 3. - P. 517-523.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Otrashevskaya E.V., Krasil'nikov I.V., Ignat'ev G.M., Atrasheuskaya A.V., Krasilnikov I.V., Ignatyev G.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies